Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Low muscle tone (hypotonia), Intellectual disability, and Global developmental delay; and common findings: Short stature, Seizure, Gastroesophageal reflux, and Pes planus and others. 50 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 12 | Seizure, Ataxia, Aggressive behavior |
Digestive system | 3 | Gastroesophageal reflux, Feeding difficulties, Chronic constipation |
Bones and joints | 3 | Excessive inward curvature of the lower spine (hyperlordosis), Joint hypermobility, Sideways curvature of the spine (scoliosis) |
Arms and legs | 2 | Prominent fingertip pads, Recurrent hand flapping |
Growth and development | 2 | Short stature, Failure to thrive |
Head and neck | 2 | High palate, Secondary microcephaly |
Heart and blood vessels | 2 | Atrial septal defect, Mitral valve prolapse |
Muscles | 1 | Low muscle tone (hypotonia) |
Age of onset: infancy.
Most individuals with HNRNPH2-related neurodevelopmental disorder (HNRNPH2-NDD) have symptoms early in life, before age 12 months. The major features of HNRNPH2-NDD are developmental delay/ intellectual disability, motor and language delays, behavioral and psychiatric disorders, and growth and musculoskeletal abnormalities. Minor features include dysmorphic facies, gastrointestinal disturbances, epilepsy, and visual defects. To date, 49 individuals from 45 families with pathogenic variants in HNRNPH2 have been identified [, , , , , ]. Initially, because the only affected individuals were phenotypic females presumed to be 46,XX, it was hypothesized that affected 46,XY individuals were embryonic lethal. However, at least 16 affected 46,XY individuals have now been reported [, , , , , ]. At least one unaffected mother of an affected female was found to have the same HNRNPH2 pathogenic variant as her daughter. This unaffected mother had significantly skewed X-chromosome inactivation . There is not enough information on affected females versus affected males to make any generalizations about phenotypic differences between the two sexes. Table 2. HNRNPH2-Related Neurodevelopmental Disorder: Frequency of Select Features
Feature | # of Personsw/Feature (%) | Comment |
|---|---|---|
HNRNPH2 encodes heterogeneous nuclear ribonucleoprotein H2 (449 aa). This protein is a component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complexes which provide the substrate for the processing events that pre-mRNAs undergo before becoming functional, translatable mRNAs in the cytoplasm. Highest expression in Brain Cerebellar Hemisphere (148.2 TPM) and Cells Cultured fibroblasts (140.1 TPM).
Intellectual disability, X-linked, syndromic, Bain type is associated with mutations in the HNRNPH2 gene on chromosome X.
HNRNPH2 is classified as a druggable target with score 17.4.
For the purposes of this GeneReview, the terms "male" and "female" are narrowly defined as the individual's biological sex at birth . No consensus clinical diagnostic criteria for HNRNPH2-related neurodevelopmental disorder (HNRNPH2-NDD) have been published.
HNRNPH2-NDD should be considered in both females and (less commonly) males with the following clinical features.
Clinical findings
Developmental delay/ intellectual disability, most often characterized by significant motor abnormalities with severe expressive and receptive language impairment
AND
Source: GeneReviews — "HNRNPH2-Related Neurodevelopmental Disorder"
Table 3. Selected Disorders of Interest in the Differential Diagnosis of HNRNPH2-Related Neurodevelopmental Disorder
Gene/ Genetic Mechanism | Disorder | MOI | Clinical Characteristics | Comment/ Distinguishing Features |
|---|---|---|---|---|
Angelman syndrome | See footnote 1. | DD/ID, speech delay, ataxic gait, limb tremulousness; happy demeanor w/frequent smiling, laughing, excitability | Persons w/Angelman syndrome have more persistent regression than those w/HNRNPH2-NDD. |
Genetic testing for HNRNPH2 is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for intellectual disability, X-linked, syndromic, Bain type. The disease remains an area of unmet medical need.
No clinical practice guidelines for HNRNPH2-related neurodevelopmental disorder (HNRNPH2-NDD) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with HNRNPH2-NDD, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with HNRNPH2-Related Neurodevelopmental Disorder
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measure growth parameters incl head circumference. | To assess for poor growth, short stature, microcephaly |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech/language eval; Eval for early intervention/ special education Psychiatric/ |
Behavioral | Neuropsychiatric eval | For persons age 12 mos: screening for behavior concerns incl sleep disturbances, ADHD, anxiety, /or traits suggestive of ASD |
Neurologic | Neurologic eval, incl assessment of tone | To consider if seizures or regression in skills are noted:; Brain MRI; EEG Movement |
disorders | Orthopedics/ physical medicine rehab/ PT OT eval |
Source: GeneReviews — "HNRNPH2-Related Neurodevelopmental Disorder"
View trials for intellectual disability, X-linked, syndromic, Bain type
Table 6. Recommended Surveillance for Individuals with HNRNPH2-Related Neurodevelopmental Disorder
System/Concern | Evaluation | Frequency |
|---|---|---|
Growth | Measurement of growth parameters | At each visit Gastrointestinal/ Feeding |
Eyes | Ophthalmologic eval | At least annually or as clinically indicated |
Hearing | Audiologic eval | At least annually in childhood or as clinically indicated |
Endocrine | Assessment for signs/symptoms of puberty1 | At each visit in childhood adolescence Family/ |
Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit GERD = gastrointestinal reflux disease; OT = occupational therapy; PT = physical therapy 1. To assess for precocious or delayed puberty |
Source: GeneReviews — "HNRNPH2-Related Neurodevelopmental Disorder"
Phenotype severity distribution: 3 always present features, 16 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for intellectual disability, X-linked, syndromic, Bain type.
2 publications have been identified in PubMed for intellectual disability, X-linked, syndromic, Bain type. Research spans Basic Science / Preclinical (100%).
Chen G (2025). [PMID: 41090715](https://pubmed.ncbi.nlm.nih.gov/41090715/). *Cells*. [Basic Science / Preclinical]
Akter H (2025). [PMID: 40671880](https://pubmed.ncbi.nlm.nih.gov/40671880/). *Genet Med Open*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
46/46 (100%) |
Typically in severe range |
Abnormal tone | 41/46 (89%) | Hypotonia (more common) hypertonia both reported |
Severe language impairment | 37/45 (82%) | Nonverbal or minimally verbal |
Psychiatric disorders | 32/42 (76%) | Anxiety, ASD, ADHD are most common. |
Facial dysmorphism | 31/44 (70%) | See Facial features, following the table. |
Feeding problems | 28/41 (68%) | Some affected persons require gastrostomy tube for feeding. |
Orthopedic problems | 25/37 (68%) | Most commonly scoliosis |
Visual defects | 29/43 (67%) | Strabismus in about half |
Seizures | 18/46 (39%) | No characteristic seizure type |
Sleep problems | 16/41 (39%) | Both falling staying asleep |
Microcephaly | 16/44 (36%) | Commonly acquired |
Hearing loss | ~25% | Developmental delay (DD) and intellectual disability (ID) has been reported in all affected individuals and is one of the major phenotypic features of HNRNPH2-NDD. The degree of disability is most commonly in the moderate-to-severe range. |
Source: GeneReviews — "HNRNPH2-Related Neurodevelopmental Disorder"
HNRNPH1 | HNRNPH1-related syndromic ID2 | AD | Common findings incl short stature, microcephaly, ID, congenital anomalies. Dysmorphic features incl blepharophimosis, ptosis, hypotelorism, medial arched eyebrows, micrognathia. | Persons w/HNRNPH1-related syndromic ID commonly have congenital anomalies dysmorphic features; most also have abnormalities of the cerebellar vermis on brain MRI. |
MECP2 | MECP2 classic Rett syndrome (See MECP2 Disorders.) | XL | Developmental regression after period of normal development; more common in females, but males have been reported; other features: slowing head growth, loss of speech, gait abnormalities, replacement of purposeful hand movements w/repetitive stereotypies | The period of normal development (followed by developmental regression) observed in classic Rett syndrome is not seen in HNRNPH2-NDD. PURA |
PURA-related neurodevelopmental disorders | AD | Presents w/ID developmental epileptic encephalopathy; characteristic neonatal features: congenital hypotonia, respiratory difficulties (most commonly due to central sleep apnea), feeding difficulties, hypersomnolence, hypothermia | 60% of persons w/PURA-NDD have drug-resistant epilepsy (most commonly Lennox-Gastaut syndrome); ~50% have abnormal MRI, most commonly delayed myelination volume loss. SLC9A6 | — |
Christianson syndrome | XL | In males, DD ID, severe speech delay, ASD or autistic behavior, hyperkinesis, epilepsy, developmental regression, truncal ataxia, acquired microcephaly, eye mvmt abnormalities, feeding difficulties. Heterozygous females are asymptomatic or have mild ID or behavioral issues. | Unlike HNRNPH2-NDD, Christianson syndrome is characteristically seen in males. Hyperkinesis is a prominent feature in affected males. | — |
Source: GeneReviews — "HNRNPH2-Related Neurodevelopmental Disorder"
To incl assessment of:; Gross motor fine motor skills; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Respiratory | Polysomnography | For those who have sleep disturbances /or signs/symptoms of sleep apnea Gastrointestinal/ |
Feeding | Gastroenterology/ nutrition/ feeding team eval | To assess nutritional status Modified barium swallow or VFSS |
Eyes | Ophthalmologic eval | To assess for vision, abnormal ocular movement, best corrected visual acuity, refractive errors, strabismus, more complex findings (e.g., cortical visual impairment) that may require subspecialty referral |
Hearing | Audiologic eval | Assess for hearing loss. |
Musculoskeletal | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Scoliosis; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Cardiovascular | Echocardiogram | To evaluate for valvar or other structural cardiac anomalies |
Endocrine | Clinical eval of pubertal status in children adolescents | To evaluate for precocious or delayed puberty; Consider referral to endocrinologist if such findings are present. Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of HNRNPH2-NDD to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with HNRNPH2-Related Neurodevelopmental Disorder Manifestation/Concern | Treatment | Considerations/Other Poor weight gain/ Failure to thrive |